The Oncology Institute (TOI)
(Delayed Data from NSDQ)
$0.49 USD
+0.02 (3.36%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $0.47 -0.02 (-3.89%) 4:24 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TOI 0.49 +0.02(3.36%)
Will TOI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TOI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TOI
Ascend Wellness Holdings, Inc. (AAWH) Reports Q2 Loss, Lags Revenue Estimates
The Oncology Institute, Inc. (TOI) Reports Q1 Loss, Lags Revenue Estimates
TOI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viatris (VTRS) Q1 Earnings and Revenues Miss Estimates
Down -23.64% in 4 Weeks, Here's Why The Oncology Institute (TOI) Looks Ripe for a Turnaround
Beat the Market Like Zacks: UnitedHealth, Casey's, Cencora in Focus
Other News for TOI
Constellation Software Inc. and Topicus.com Inc. Announce Results for Topicus.com Inc. for the Second Quarter Ended June 30, 2024
Topicus.com Inc. Showcases Strong Q2 Financial Growth
The Oncology Institute Announces Second Quarter 2024 Earnings Release Date and Conference Call
Topicus.com Inc. Announces Release Date for Second Quarter Results
12 Health Care Stocks Moving In Tuesday's After-Market Session